Xolair Push For Younger Patients Could Test Power Of Risk Management
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Pulmonary-Allergy Drugs Advisory Committee will meet Nov. 18 to review the asthma drug to treat patients between six and 11 years of age.